Under construction – not a live service
Sign in
Not yet taking people in ArgentinaPhase 3

Eloralintide and tirzepatide combined for weight loss in adults with obesity

Tests eloralintide with tirzepatide for weight loss in adults with obesity.

Plain-language title generated from the registry record
Registry title: A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes

Key facts

Where
Bahía Blanca, Buenos Aires, Ciudad de Buenos Aires, Córdoba, Del Viso, Godoy Cruz, Granadero Baigorria, Junín, Mar del Plata, Mendoza, Rosario, SAN M. de Tucuman, and Santiago del Estero, ArgentinaSee the 20 sites
Phase
Phase 3

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with obesity who do not have diabetes. It compares a combined drug (eloralintide and tirzepatide) with tirzepatide alone, eloralintide alone and placebo for weight loss.

Age
18 years or older
Sex
Men and women can join
Disease stage
Obesity with a BMI of 35 kg/m2 or more at screening. No diabetes of any type.
Earlier treatment
At least 1 self-reported unsuccessful diet attempt to lose weight. Stable body weight (less than 5% change) for 90 days before screening. No glucose-lowering medication and no weight-loss medication or remedies in the 90 days before screening.

Main reasons for not taking part

  • Type 1 diabetes, type 2 diabetes or any other type of diabetes
  • Prior or planned surgery for obesity, with limited exceptions if done more than 1 year before screening
  • Prior or planned endoscopic procedure or device-based therapy for obesity or type 2 diabetes, with an exception if the device was removed more than 6 months before screening
  • Heart attack, stroke, coronary artery revascularization, unstable angina or hospital stay for heart failure in the 90 days before screening
  • New York Heart Association Class IV congestive heart failure

Read by machine on 9 November 2026.

Where in Argentina

  • Instituto de Investigaciones Clínicas Bahia BlancaBahía Blanca, ArgentinaContact: Daniel Vogel (principal investigator)No longer taking part
  • CEMEDICBuenos Aires, ArgentinaContact: Olga Paez (principal investigator)No longer taking part
  • Centro Medico Dra. Laura Maffei- Investigacion Clinica AplicadaBuenos Aires, ArgentinaContact: Antonela Mainardi (principal investigator)No longer taking part
  • Centro Médico ViamonteBuenos Aires, ArgentinaContact: Diego Aizenberg (principal investigator)No longer taking part
  • Cicemo SrlBuenos Aires, ArgentinaContact: Alejandro de Dios (principal investigator)No longer taking part
  • Consultorio Medico Investigador Principal Dr BesadaBuenos Aires, ArgentinaContact: Diego Besada (principal investigator)No longer taking part
  • DOLZ Investigación ClínicaBuenos Aires, ArgentinaContact: Mariano Dolz (principal investigator)No longer taking part
  • Mautalen Salud e InvestigaciónBuenos Aires, ArgentinaContact: Jose Fretes (principal investigator)No longer taking part
  • IDIM - Instituto de Investigaciones MetabólicasCiudad de Buenos Aires, ArgentinaContact: Maria Zanchetta (principal investigator)No longer taking part
  • Centro Medico Privado San Vicente DiabetesCórdoba, ArgentinaContact: Mariana Peralta (principal investigator)No longer taking part
  • MICA - Medicina e Investigación CardiometabólicaDel Viso, ArgentinaContact: Micaela Mirada (principal investigator)No longer taking part
  • Hospital Español de MendozaGodoy Cruz, ArgentinaContact: Matias Arrupe (principal investigator)No longer taking part
  • Centro de Investigaciones Clínicas BaigorriaGranadero Baigorria, ArgentinaContact: Juan Dominguez (principal investigator)No longer taking part
  • CMD-Centro Médico y Diagnóstico por ImágenesJunín, ArgentinaContact: Maria Pelagagge (principal investigator)No longer taking part
  • Centro de Investigaciones Medicas Mar Del PlataMar del Plata, ArgentinaContact: Andres Alvarisqueta (principal investigator)No longer taking part
  • Instituto de Cardiología WolffMendoza, ArgentinaContact: SEBASTIAN WOLFF (principal investigator)No longer taking part
  • Instituto Médico Catamarca IMECRosario, ArgentinaContact: Natacha Maldonado (principal investigator)No longer taking part
  • Instituto Médico Fundación Grupo Colaborativo Rosario Investigación y Prevención MedicaRosario, ArgentinaContact: Horacio Sessa (principal investigator)No longer taking part
  • Centro de Investigaciones Médicas TucumanSAN M. de Tucuman, ArgentinaContact: Magdalena Martinez Romero (principal investigator)No longer taking part
  • Sanatorio NorteSantiago del Estero, ArgentinaContact: Franklin Abalos (principal investigator)No longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Eli Lilly and Company
Trial code
NCT07881432EU 2026-526047-34-00
Record updated
3 November 2026
Original description
The purpose of this study is to investigate the efficacy and safety of eloralintide and tirzepatide coformulation (EloraTZP) compared with tirzepatide, eloralintide and placebo for body weight reduction in participants with obesity.Read full original descriptionShow less

A Phase 3 Study to Investigate the Efficacy and Safety of LY900043 in Adult Participants With Obesity Without Type 2 Diabetes

The purpose of this study is to investigate the efficacy and safety of eloralintide and tirzepatide coformulation (EloraTZP) compared with tirzepatide, eloralintide and placebo for body weight reduction in participants with obesity.

Participation in the study will last about 2 years.

Inclusion: Have a stable self-reported body weight (<5% body weight change) for 90 days prior to screening; Have a BMI of ≥35 kg/m2 at screening; Have a history of at least 1 self-reported unsuccessful dietary effort to reduce body weight.

Exclusion: Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening); Have a prior or planned endoscopic procedure and/or device-based therapy for obesity and/or type 2 diabetes (prior device-based therapy acceptable if device removal was more than 6 months prior to screening); Have had within 90 days prior to screening:; heart attack; stroke; coronary artery revascularization; unstable angina, or; hospitalization due to congestive heart failure; Have taken medications or alternative remedies intended for weight loss within 90 days of screening; Have type 1 diabetes, type 2 diabetes, or any other type of diabetes; Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure; Have taken any glucose-lowering medication within 90 days of screening.

ClinicalTrials.gov NCT07881432 · EU CTIS 2026-526047-34-00